Our Consulting Services

Craig Crosson
Executive Director

For over 30 years my NIH-funded laboratory worked to understand the molecular and cellular events responsible several blinding diseases.  While these efforts formed the basis for new glaucoma therapeutics, the direct impact on improving the quality of life for afflicted individuals was limited.

In contrast, for almost 30 years OSOD has conducted hundreds of studies that help companies advance the development of new drugs and devices.  These studies have directly led to new approved treatments for conditions ranging from age-related macular degeneration to dry eye.  Collaborations we have established with the scientists, physicians and regulatory experts in academia and the development industry allows us to apply an extensive and comprehensive suite of services to ophthalmic drug and device development.  

Collaboration with individuals and organizations who are changing the quality of life for people around the world is a unique opportunity and I am honored to be part of this exceptional team.  Our shared passion can be simply stated by “how can we help.”

We apply our team’s deep knowledge of vision science and wide breadth of technical and development expertise to advance therapies

Vision Science

Our academic experts have deep knowledge and investigative experience in most vision science disciplines.  

​Technical Expertise

​Our technical experts understand the species-related and logistical factors critical and to acquiring high quality ophthalmic data.  We have worked with all relevant lab species and can advise on optimal study design and planning.

Chemistry Manufacturing and Control

​OSOD members aid in identifying endpoints and designing procedures needed to assess the physical and chemical characteristics of drug products to ensure their consistent quality during manufacturing.  Our members also help in submitting this information to regulatory authorities.

Regulatory and Development Guidance

OSOD industry members have extensive experience developing drugs and devices, including the successful approval of ocular therapies.    We can advise on target pathway biology, preclinical POC, PK and safety, as well as clinical testing strategy.

​Investigative Diligence

Our vision science, physician and industry experts have the experience needed to evaluate the potential of new assets for ocular therapy development, as well as a track record of success.